ArticleToxicology research2025
Zearalenone induces GnRH neurons activation related to central precocious puberty by triggering MKRN3 auto-ubiquitination and down-regulation.
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central precocious puberty (CPP) refers to gonadotropin-dependent sexual precocity that results from the early activation of the hypothalamic-pituitary-gonadal (HPG) axis. Zearalenone (ZEA), a non-steroidal mycotoxin, is one of the important triggering factors for the development of CPP; however, its regulatory mechanism remains unclear. In this study, the correlation between urinary zearalenone (ZEA) levels and the blood expression of MKRN3 (makorin RING-finger protein-3) in patients with central precocious puberty (CPP) was investigated. Subsequently, the regulatory mechanism of ZEA on MKRN3, as well as its association with gonadotropin-releasing hormone (GnRH) production, cell proliferation, and the expression and localization of the G protein-coupled estrogen receptor (GPER) were explored in the hypothalamic cell line GT1-7. Analysis of clinical samples revealed that urinary ZEA levels were negatively correlated with blood MKRN3 expression in CPP patients. The in vitro experiments revealed that ZEA treatment up-regulated cell proliferation as well as the expressions of GnRH and GPER and re-location of GPER in GT1-7 cells by triggering MKRN3 auto-ubiquitination and down-regulation. However, such effects were attenuated by GPER overexpression. In conclusion, this study reveals a novel mechanism by which ZEA influences CPP using clinical samples and an in vitro model. The findings suggest that MKRN3 may serve as a potential therapeutic target and a diagnostic biomarker for CPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.